SCHEMBL2820368

SCHEMBL2820368

CCOC1c2ccccc2C(n2cncc2C(=O)OC)C1(C)C

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 4/20 0.54
MAPK1 P28482 1/20 0.39
IDO1 P14902 9/20 0.38
ADRA2A P08913 1/20 0.36
ADRA2B P18089 1/20 0.36
ADRA2C P18825 1/20 0.36
ADRA1B P35368 1/20 0.36
GABRA1 P14867 4/20 0.35
GABRB2 P47870 4/20 0.35
CYP11B1 P15538 3/20 0.35
CYP1A2 P05177 2/20 0.35
CYP3A4 P08684 2/20 0.35
LMNA P02545 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
ABCB11 O95342 1/20 0.35
GABRA2 P47869 1/20 0.35
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
GLA P06280 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2820370 1.00 CYP11B2 (0.54) CYP11B2MAPK1IDO1ADRA2AADRA2B
SCHEMBL2820379 1.00 CYP11B2 (0.54) CYP11B2MAPK1IDO1ADRA2AADRA2B
SCHEMBL9494229 0.89 CYP11B2 (0.47) CYP11B2MAPK1IDO1ADRA2AADRA2B
SCHEMBL9777356 0.83 CYP11B2 (0.48) CYP11B2MAPK1IDO1GABRA1GABRB2
SCHEMBL9777272 0.80 CYP11B2 (0.48) CYP11B2MAPK1IDO1GABRA1GABRB2
SCHEMBL9493949 0.79 CYP11B2 (0.45) CYP11B2MAPK1IDO1GABRA1GABRB2
SCHEMBL2820744 0.77 CYP11B2 (0.43) CYP11B2MAPK1IDO1KDM4EALDH1A1
SCHEMBL2820750 0.77 CYP11B2 (0.43) CYP11B2MAPK1IDO1KDM4EALDH1A1
SCHEMBL2820747 0.77 CYP11B2 (0.43) CYP11B2MAPK1IDO1KDM4EALDH1A1
SCHEMBL2821140 0.76 CYP11B2 (0.60) CYP11B2MAPK1IDO1CYP11B1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436035-B2 Organic compounds NOVARTIS AG (CH) 2013-05-07 US disclosed
US-8436035-B2 Organic compounds NOVARTIS AG (CH) 2013-05-07 US disclosed
US-8436035-B2 Organic compounds NOVARTIS AG (CH) 2013-05-07 US disclosed
EP-2213668-A2 Imidazoles as aldosterone synthase inhibitors Novartis AG (CH) 2010-08-04 EP disclosed
US-20100048562-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2010-02-25 US disclosed
US-20100048562-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2010-02-25 US disclosed
US-20100048562-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2010-02-25 US disclosed
EP-2094680-A2 IMIDAZOLES AS ALDOSTERONE SYNTHASE INHIBITORS Novartis AG (CH) 2009-09-02 EP disclosed
WO-2008076336-A2 IMIDAZOLES AS ALDOSTERONE SYNTHASE INHIBITORS NOVARTIS AG (CH) 2008-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048562-A1 ORGANIC COMPOUNDS CYP11B1, HSD11B1, CYP17A1 CYP11B2 6/4885MAPK1 977/4885IDO1 1361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.